Guidance on the use of taxanes for ovarian cancer
National Institute for Clinical Excellence
Record ID 32000000048
English
Authors' objectives:
To provide guidance on the use of taxanes for the treatment of ovarian cancer.
Authors' recommendations:
Guidance
1.1 Paclitaxel in combination with a platinum therapy (cisplatin or carboplatin) should be the standard initial therapy for patients with ovarian cancer following surgery.
1.2 The use of paclitaxel/platinum combination therapy in the treatment of recurrent (or resistant) ovarian cancer is recommended if the patient has not previously received this drug combination. If the patient has already received both drugs, the combination of paclitaxel and platinum-based therapy in recurrent (or resistant) ovarian cancer is not recommended, outside the context of clinical trials.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
http://www.nice.org.uk/page.aspx?o=ta003
Year Published:
2000
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antineoplastic Agents
- Ovarian Neoplasms
Contact
Organisation Name:
National Institute for Clinical Excellence
Contact Address:
MidCity Place, 71 High Holborn, London WC1V 6NA, UK. Tel: +44 020 7067 5800; Fax: +44 020 7067 5801
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.